| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Michael D Hooven last filed a Form 4 in May 2017, as Director at ATRC. Michael D Hooven's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 67,049 shares of ATRC. The ATRC filings lean toward selling, a net 152,268 shares.
Michael D Hooven has 4 Form 4 filings on record from March 2015 to May 2017, all as Director at AtriCure (ATRC), 2015–2017.
The 10 reported transactions were 7 open-market sales, 2 option or other derivative awards and 1 option exercise.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $3.2M.
The largest open-market sale was 142,268 shares of ATRC at an average $20.81 on April 1, 2015, about $3.0M.
Shares as reported in the last Form 4 for each company; the most recent is from May 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.